anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Language delay affects near- and long-term social communication and learning in toddlers, and, an increasing number of experts pay attention to it. The development of prosody discrimination is one of the earliest stages of language development in which key skills for later stages are mastered. Therefore, analyzing the relationship between brain discrimination of speech prosody and language abilities may provide an objective basis for the diagnosis and intervention of language delay.
METHODS: In this study, all cases(n = 241) were enrolled from a tertiary women's hospital, from 2021 to 2022. We used functional near-infrared spectroscopy (fNIRS) to assess children's neural prosody discrimination abilities, and a Chinese communicative development inventory (CCDI) were used to evaluate their language abilities.
RESULTS: Ninety-eight full-term and 108 preterm toddlers were included in the final analysis in phase I and II studies, respectively. The total CCDI screening abnormality rate was 9.2% for full-term and 34.3% for preterm toddlers. Full-term toddlers showed prosody discrimination ability in all channels except channel 5, while preterm toddlers showed prosody discrimination ability in channel 6 only. Multifactorial logistic regression analyses showed that prosody discrimination of the right angular gyrus (channel 3) had a statistically significant effect on language delay (odd ratio = 0.301, P < 0.05) in full-term toddlers. Random forest (RF) regression model presented that prosody discrimination reflected by channels and brain regions based on fNIRS data was an important parameter for predicting language delay in preterm toddlers, among which the prosody discrimination reflected by the right angular gyrus (channel 4) was the most important parameter. The area under the model Receiver operating characteristic (ROC) curve was 0.687.
CONCLUSIONS: Neural prosody discrimination ability is positively associated with language development, assessment of brain prosody discrimination abilities through fNIRS could be used as an objective indicator for early identification of children with language delay in the future clinical application.
Friendly Visitor (FV) calls delivered via videoconferencing by a trained FV interventionist; 5 sessions over 5 weeks, up to 1-hour in length. The interventionist provides social support to participants through good listening and provision of genuine regard.
Participants in the pioglitazone group were administered a pioglitazone tablet (15 mg) once a day. In the event of the side effects such as oedema, the dosage of pioglitazone was reduced to half or a quarter of the original dosage. Otherwise, we tried to increase the dose of pioglitazone to 30mg/day.
Patient will meet with an exercise specialist once per week for the first 6 weeks. Patients will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks.
Patients participate in three 15-minute YST sessions, comprising awareness meditation practice, movement practice, and breathing practice and relaxation. Patients also receive a CD recording of a 15-minute YST session and are instructed to practice the YST at home 4 times weekly.
BACKGROUND: An older person undergoes a 'disablement' process with aging. A comprehensive geriatric assessment centered around the functional status informs the healthcare provider of their frailty status, based on which tailored interventions may be designed to help prevent/reverse frailty. This study was conducted to assess the improvement in frailty index by training older persons for self-care practices using a multi-domain behavioural intervention, assisted by their caregivers.
METHODS: It is a community-based interventional trial among older persons aged ≥ 60 years and their primary caregivers conducted in an urban community for a period of 15 months. A hybrid model, which exploits the advantages of every indigenous geriatric model of care, in providing a holistic care to old persons, was developed and adopted. Intervention was designed to incorporate all domains of frailty assessed, based upon self-efficacy and social interdependence theory. Frail-VIG scale and SPPB scores were used to measure the outcomes.
RESULTS: 128 older persons and their primary caregivers were recruited. Median age was 70 and 67 years in the intervention and control group respectively, with majority being males. The median frailty index at baseline was 0.36 in both the groups, with improvement in intervention group (0.20) and worsening in control group (0.44) at end-line. From the DID analysis, a reduction of 0.19 points of frailty index was observed (even after adjustment for co-variates) in the intervention group, as compared to the control group. Also, it was observed that age and gender of the old person, their per capita income and the family support played an interactive effect in improvement of the frailty index. There was a significant difference in SPPB scores as well, between the groups [5 (1) in CG vs. 7 (2) in IG, p < 0.001].
CONCLUSION: Frailty could be reversed with appropriate interventions designed on the pillars of self-efficacy, and social interdependence among family members. The hybrid model of care delineates the role of caregivers, who reinforce the old persons to follow prescribed interventions.
Twenty four hour blood pressure variability will be assessed. This will be performed while subjects are on a low sodium diet (1000 mg/daily), medium sodium diet (2300 mg/daily), and high sodium diet (7000 mg/daily).
PURPOSE:To obtain a bathing agent for children capable of arousing a desire for bathing and making the children take an interest and fun thereat by constructing a container body of a shape with character properties from a synthetic resin having resiliency and sealing an opening for releasing bath water with a hermetic sealing agent soluble in water or warm water. CONSTITUTION:A container body 1 having a chamber (1A) is formed from a synthetic resin with resiliency so as to impart a pump function thereto. The outer shape of the container body 1 is provided with a character acceptable with children. A bath liquid (W) (e.g. bath oil) in an amount for use at one time is filled in the chamber (1A) and an opening (2A) of a discharge port 12 for the aforementioned bath liquid is sealed with a hermetic sealing agent (P) (e.g. gelatin, PVA or starch) readily soluble in water, warm water, etc.
Control Group intervention: No intervention first 3 months. After 3 months of follow-up, half of the patients in the Control Group will be randomized to perform home blood pressure monitoring as an intervention. No intervention in the other half.
This is a Phase 1 double-blinded, placebo-controlled, dose-escalation trial to evaluate the safety and immunogenicity of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by oral, sublingual, or intradermal vaccination in approximately 135 healthy adult volunteers, age 18-45 years, who meet all the eligibility criteria and reside in Bangladesh. Study duration is approximately 2.5 years, with each participant duration for up to 9 months depending on the route of dmLT administered. The study population will be recruited from Mirpur, a community of Dhaka, Bangladesh, known as having a high rate of diarrheal, respiratory, and enteric disease. This clinical trial is designed to assess the safety, reactogenicity, tolerability, and immunogenicity of a range of dosages of dmLT administered by three different routes: oral, sublingual, or intradermal. The oral and sublingual routes of administration will evaluate dosages of 5, 25, and 50 micrograms of dmLT; the intradermal route of administration will evaluate dosages of 0.3, 1.0, and 2.0 micrograms of dmLT. Participants will receive a total of three sequential doses of dmLT; the oral and sublingual routes will be at days 1, 15, and 29 and the intradermal route will be at days 1, 22, and 43. There is no specific hypothesis being tested in this study. The primary objective of this study is to assess the reactogenicity, safety, and tolerability of dmLT when administered in three sequential doses, over a range of dosages by oral, sublingual, or intradermal routes. The secondary objectives of this study are: 1) to assess the long-term safety, from first vaccination through 6 months following the last dose of vaccine, 2) to evaluate the serum anti-dmLT IgG and IgA response, 3) to evaluate the IgG and IgA anti-dmLT Antibody Secreting Cell (ASC) response, 4) to evaluate the IgG and IgA anti-dmLT Antibodies in Lymphocyte Supernatant (ALS) response, 5) to evaluate the total fecal IgA and fecal anti-dmLT IgA response, and 6) to evaluate the total salivary IgA and the saliva-derived anti-dmLT IgA response.
A dietary supplement composition is provided for enhancing the expression of a sirtuin gene or protein. An inventive supplement composition includes at least one cinnamon extract containing at least 0.5% doubly linked Type-A polymers by dry weight. The cinnamon extract is derived from the  Cinnamonum aromaticum, Cinnamonum verum or Cinnamonum burmannii  plant. In some embodiments, the cinnamon extract is present at approximately 20%-50% of the dry weight of the composition. A vitamin, weight loss agent, or antioxidant is optionally provided in the composition. The dietary supplement composition is administered orally to promote expression or enhanced expression of a sirtuin gene or protein.
In order to apply medications in the form of active substances bound in a liquid or paste-like matrix in the ear canal, the invention proposes a novel means (1) able to absorb and locally deliver a medication. Said means comprises a sack-like receptacle part (2) in which a preferably textile tampon able to absorb the medication can be accommodated, and an elastic rubber retaining washer (3) serving to fix the receptacle part (2) in the outer ear. The receptacle part (2) is firmly connected to a pulling device (4), such as a string, via the retaining washer (3). The retaining washer (3) serves to fix the receptacle part (2) in the outer ear canal and is supported for that purpose on one side behind the anthelix (106) and on the other side behind the tragus (108). In a preferred embodiment, the retaining washer (3) is made from a flat material stamped from foam rubber. The applicator can be sold with a charge of medication.
The children and adolescent 6-15 years old with ADHD. Diagnoses of the children with ADHD were made in Xijing Hospital according to criteria described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Children with ADHD had an IQ score above 70.
FIELD: medicine, cardiology. SUBSTANCE: the innovation refers to indenoilguanidine of formula I,   method for its obtaining and medicinal preparation based upon it. Compounds are very useful to treat cardiac arrhythmia. Moreover, they are used as mammalian cardioprotective agents. It is, also, described the method to obtain necessary compounds. EFFECT: higher efficiency of therapy. 6 cl, 7 tbl
Mental health organizations will be randomized to two study groups. Within each organization, clinicians will be recruited. Within clinician practices, clients will be recruited. Baseline data will be collected from the two groups of mental health organization leads, clinicians, and clients. Both groups will undergo data collection with 5 tools by research teams: at the organization level the Organizational Climate Assessment and at the clinician level the Provide Self-Assessment during month 1 of each site's participation. Client level Client Satisfaction Survey data will also be collected during month 1 of each site's participation (cohort 1 clients). During months 2-4 of each site's participation, clinicians in the control group will receive standard nationally, publicly freely accessible information, specifically a letter notifying them about the on-line accessible SAMHSA LGBT services education manual and Fenway Health Webinars. In the intervention group, clinicians will also receive a letter notifying them about the nationally, publicly freely accessible on-line SAMHSA education manual and Fenway Health Webinars plus they will receive a 1-day, clinician training followed by 4 biweekly 2-hour technical assistance workshops to review and address information gleaned from the 5 tool's and to finalize the problem-solving related to needs for change based on the 5 tool's. During month 5 of each site's participation, both groups will undergo follow-up data collection and assessment by research teams at the organization and clinician levels. Client level data will also be collected during month 5 of each site's participation (cohort 2 clients). Finally, during month 6 of each site's participation, each site's 5 clinicians in both study arms will complete one first-time consultation session by screen-to-screen interaction via on-line computer interface with a LGBT standardized patient so that their objective skill-level performance can be assessed.
PCT No. PCT/US96/17124 Sec. 371 Date Oct. 2, 1998 Sec. 102(e) Date Oct. 2, 1998 PCT Filed Oct. 25, 1996 PCT Pub. No. WO97/17939 PCT Pub. Date May 22, 1997A spray-dried, granular powder comprising: (i) from about 50% to about 99% of a water-soluble carrier, (ii) from about 1% to about 50% of a hydrophobic silicone oil dispersed within the carrier, wherein the spray-dried powder has a volume average particle size in the range from about 20  mu m to about 500  mu m, the powder being prepared by spray-drying an aqueous dispersion of the silicone oil and the water-soluble carrier, characterized in that the silicone oil is present in the dispersion in the form of discrete droplets having a volume average droplet size in the range from about 0.5  mu m to about 20  mu m and that the ratio of the average spray-dried particle size to the average droplet size is at least about 2.5:1. The powder is dry, free-flowing and processable into a punched tablet or other compressed forms, yet efficiently delivers the silicone oil on subsequent dissolution in water.
Pharmaceutical liposomal formulations for photodynamic therapy are presented, which are stable in storage as liquid formulations, comprise a hydrophobic photosensitizer and one or more synthetic phospholipids. The liposomal formulations provide therapeutically effective amounts of the photosensitizer for intravenous administration. The formed liposomes contain the hydrophobic photosensitizer within the lipid bilayer membrane. In the present formulation the size of the liposomal vehicles and their content of a therapeutically effective amount of the photosensitizing agent remain unchanged over storage times of a year or more, thus making the liquid formulations commercially viable. Being stable in the liquid state also makes them easy to store, and easier to use for doctors and patients. They can be prepared in a ‘factory setting’ delivered to practitioners in a liquid state and be available for use in PDT related treatments as called for by the practitioners' patient needs.
Compositions which include a complex of a biologically active agent and a cyclodextrin, which is encapsulated in a polymer, and methods of preparation and use thereof are disclosed. The polymers are preferably water-insoluble, biodegradable polymers such as a polyanhydride, polyester, or polylactone. The biologically active agent includes reactive groups which would react with the polymers if it was not complexed with a cyclodextrin. In addition to minimizing or preventing interactions between the agent and the polymer, the cyclodextrin helps provide more linear release of the incorporated agent rather than burst release, acts as a surfactant to help stabilize emulsions during microparticle preparation, and allows for improved re-suspension of lyophilized microparticles relative to particles that do not include a cyclodextrin. In addition, cyclodextrin drug complexes can be loaded to contain higher concentrations of a drug than complexes without cyclodextrin. The devices and particles can be used to deliver therapeutic, prophylactic and/or diagnostic agents to a patient in need thereof.
The sustained success of Mycobacterium tuberculosis as a pathogen arises from its ability to persist within macrophages for extended periods and its limited responsiveness to antibiotics. Furthermore, the high incidence of resistance to the few available antituberculosis drugs is a significant concern, especially since the driving forces of the emergence of drug resistance are not clear. Drug-resistant strains of Mycobacterium tuberculosis can emerge through de novo mutations, however, mycobacterial mutation rates are low. To unravel the effects of antibiotic pressure on genome stability, we determined the genetic variability, phenotypic tolerance, DNA repair system activation, and dNTP pool upon treatment with current antibiotics using Mycobacterium smegmatis. Whole-genome sequencing revealed no significant increase in mutation rates after prolonged exposure to first-line antibiotics. However, the phenotypic fluctuation assay indicated rapid adaptation to antibiotics mediated by non-genetic factors. The upregulation of DNA repair genes, measured using qPCR, suggests that genomic integrity may be maintained through the activation of specific DNA repair pathways. Our results, indicating that antibiotic exposure does not result in de novo adaptive mutagenesis under laboratory conditions, do not lend support to the model suggesting antibiotic resistance development through drug pressure-induced microevolution.
The purpose of this research is to gather information on whether using quantitative- or numerical measurements of pupil changes as an alternative to qualitative- or observation based- testing can be done to assess optic nerve dysfunction in ON, MS with ON, and NMOSD with ON. One way this is done is through evaluating relative afferent pupillary defect (RAPD), which is a clinical sign that is used to detect an injury or defect in the pupil's pathway and this often involves the retina of the eye, which focuses light, and the optic nerve, which sends visual information to the brain. When shining a light into each eye, the eye with RAPD shows a slowed response to light, and when the light moves to the normal eye, the pupil of RAPD eye will dilate. Observational evaluations of RAPD are very common in clinical neurology to detect these optic nerve diseases. As technology has advanced, to lessen the observation errors, numerical measurement of RAPD is now possible through a web based app called Reflex (Brightlamp Inc., Purdue University), which is a FDAapproved class I regulated medical device. In this study, the investigator will compare the results of a participant's app recording to other data that has been collected which also tracks optic nerve function status.
The present invention is directed toward a transdermal device comprising a backing material that has low moisture transmission, moderate to high oxygen transmission, good resistance to component diffusion, and good flexibility. In one aspect, the invention comprises a transdermal drug delivery device comprising a reservoir and a multilayer polymeric film backing. The reservoir comprises a pharmaceutically active agent. The multilayer polymeric film backing comprises an outer shell layer, an inner shell layer, and an inner core between the outer shell layer and the inner shell layer comprised of 11 or more alternating layers of a thermoplastic elastomer and an olefinic polymer, wherein the weight ratio of thermoplastic elastomer to olefinic polymer in the core is below about 85:15 and above about 5:95. The inner shell layer is adjacent to the reservoir and interposed between the outer shell layer and the reservoir. At least one of the shell layers comprises a polymer selected from the group consisting of a homopolymer of polypropylene, a copolymer of polypropylene, a homopolymer of poly-4-methyl-1-pentene, a copolymer of poly-4-methyl-1-pentene, and a blend thereof.
FIELD: medicine, virology. SUBSTANCE: invention relates to preparing vaccine and diagnostic measles virus preparations. Method involves infection of human diploid cellular culture with measles virus in supporting medium. Human embryo lung fibroblasts - HELF 385/13 are used as a diploid cellular culture. Supporting nutrient medium used for measles virus culturing has the following composition by the first variant, vol.%: medium-199, 40-58; Eagle MEM medium with double content of amino acids, 40-58; aminopeptide, up to 100. By the second variant supporting medium has the following composition, vol. %: medium-199, 40-59; Eagle medium with double content of amino acid, 40-59; arginine, up to 100. Method increases the yield and biological activity of measles virus preparations and provides sufficient purity and stability of the end product. EFFECT: increased yield, improved quality and activity of preparations. 3 cl, 3 tbl, 4 ex
An apparatus for extracorporeal blood treatment comprises a control unit (100) connected to a blood pump (10) configured to deliver a blood flow rate in a blood circuit of the apparatus (1), to a diuretic pump (27) configured to deliver a flow rate (Qd) of a 5diuretic (e.g. furosemide) and to an osmotic agent pump (30) configured to deliver a flow rate (Qoa) of an osmotic agent (e.g. albumin) to be infused in the blood circuit or in the vascular system of the patient (P). The control unit (100) is configured for receiving at least one input patient parameter (e.g. blood 10pressure) and/or at least one input apparatus parameter (e.g. access pressure) and, during an extracorporeal blood treatment, to drive the diuretic pump (27) and/or the osmotic agent pump (30) as a function of said at least one input patient parameter and/or as a function of at least one input apparatus parameter, in order to15achieve an improved and better fluid removal from the patient (P).
Rosa rugosa is a medicinal plant known for its potential anti-inflammatory, antioxidant, anti-cancer, and antimicrobial benefits. The pharmacological effects of Rosa rugosa extract on hair loss have not yet been documented. This research sought to assess the inhibitory effects and mechanisms of action of Rosa rugosa water extract (RWE) in a mouse model of dihydrotestosterone (DHT)-induced alopecia. The study was conducted using C57BL/6 mice, which were assigned to five groups: control, DHT-treated, Rosa rugosa water extract (RWE) at doses of 25 mg/kg and 100 mg/kg body weight, and bicalutamide-treated. To induce hair loss, dihydrotestosterone (1 mg/day per body weight) was administered via intraperitoneal injections, and dorsal hair removal was timed to align with the telogen phase. Each group received oral treatments for a period of 23 days. In this study, we assessed hair growth activity, examined histological changes, and performed immunoblot analysis. We noted improvements in hair length and thickness. Additionally, the protein expression of growth factors associated with hair growth, including vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and insulin-like growth factor-1 (IGF-1), showed significant increases in the group treated with RWE. Additionally, treatment with RWE suppressed the protein expression of hair growth inhibitory factors, including dickkopf WNT signaling pathway inhibitor 1 (DKK1) and interleukin (IL)-6. Moreover, hair growth regulatory pathway related factors, including ERK, AKT, and GSK-3β, were activated. These findings indicate that RWE could serve as a promising natural therapy for preventing hair loss by enhancing the production of factors that promote hair growth while inhibiting those that suppress it.